Skip to main content

Table 6 Ductal breast cancer risk in relation to high-risk haplotypes, stratified by breast cancer risk factors

From: Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study

Factor Number, cases/controls c.454-351A→G c.975C→G AC haplotype c.454-397C→T c.975C→G TC haplotype
   Haplotype proportion, cases/controls OR (95% CI)a, 1 v. 0 copiesb Haplotype proportion, cases/controls OR (95% CI)a, 1 v. 0 copiesb
All ductal cancer cases 1148/1511 0.531/0.484 1.19 (1.06–1.33) 0.412/0.373 1.19 (1.06–1.34)
BMI      
   <25 549/761 0.525/0.517 1.04 (0.89–1.23) 0.404/0.388 1.08 (0.91–1.27)
   25-<28 299/429 0.531/0.458 1.32 (1.06–1.64) 0.391/0.348 1.21 (0.97–1.51)
   ≥ 28 300/321 0.541/0.456 1.41 (1.12–1.77) 0.449/0.357 1.48 (1.17–1.88)
Parity      
   0 158/134 0.495/0.472 1.14 (0.82–1.60) 0.399/0.388 1.11 (0.80–1.54)
   1 248/258 0.535/0.439 1.43 (1.10–1.84) 0.422/0.349 1.35 (1.04–1.74)
   2+ 706/1043 0.535/0.496 1.17 (1.01–1.34) 0.413/0.377 1.17 (1.02–1.35)
Menopausal hormone treatment      
   <2 years 861/1169 0.533/0.482 1.23 (1.08–1.40) 0.416/0.374 1.21 (1.06–1.38)
   ≥ 2 years 251/266 0.515/0.490 1.08 (0.84–1.40) 0.391/0.369 1.08 (0.84–1.40)
Family history      
   No 935/1246 0.528/0.486 1.18 (1.04–1.33) 0.413/0.368 1.21 (1.07–1.30)
   Yes 183/128 0.548/0.505 1.17 (0.84–1.63) 0.403/0.425 0.93 (0.67–1.30)
Age at menopause      
   ≤ 49 years 324/506 0.555/0.496 1.25 (1.02–1.54) 0.431/0.385 1.25 (1.01–1.54)
   49.5–51.5 years 445/503 0.511/0.470 1.19 (0.98–1.43) 0.397/0.356 1.19 (0.98–1.45)
   ≥ 52 years 372/489 0.534/0.494 1.18 (0.97–1.44) 0.411/0.372 1.17 (0.96–1.44)
  1. BMI, body mass index. aAge-adjusted odds ratio and 95% confidence interval. bThe odds ratios (ORs) and CIs for two copies versus none are not shown because under a model of multiplicative penetrance the OR for two copies versus none is the square of the OR for one copy versus none.